But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.